Reply to: “Improving the Reporting of Long-Term Effects in the IMpower010 Trial” and “Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity”

Enriqueta Felip; Heather A. Wakelee; Chenqi Fu; Yu Deng; Fanny Masson; Barbara Gitlitz

doi:10.1200/jco-25-02102

Reply to: “Improving the Reporting of Long-Term Effects in the IMpower010 Trial” and “Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity”

E Enriqueta Felip (Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona) H Heather A. Wakelee C Chenqi Fu Y Yu Deng F Fanny Masson (Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA) B Barbara Gitlitz (Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA)

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Journal of Clinical Oncology

Volume / Issue Vol. 44, Issue 4

Published February 01, 2026

Pages 343-344

DOI 10.1200/jco-25-02102

ISSN 0732-183X

Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (6)

E

Enriqueta Felip

Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona

H

Heather A. Wakelee

C

Chenqi Fu

Y

Yu Deng

F

Fanny Masson

Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA

B

Barbara Gitlitz

Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA

Reply to: “Improving the Reporting of Long-Term Effects in the IMpower010 Trial” and “Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity”

Article Details

Journal Info

Authors (6)

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer